Drugs / Verzistobart
Verzistobart
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06290622 | Aug 2024 → Jun 2026 | diffuse large B-cell lymphoma, follicular lymphoma | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 1 | NCT03652077 | Sep 2018 → Aug 2021 | cervical cancer, cutaneous neuroendocrine carcinoma, esophageal cancer, gastric cancer +11 | Incyte Corporation | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04370704 | Jul 2020 → Aug 2025 | melanoma | Incyte Corporation | Completed | No outcome recorded |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT06056895 | Nov 2023 → Jan 2027 expected | cutaneous neuroendocrine carcinoma | University of Washington | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05287113 | Nov 2022 → Mar 2025 | head and neck cancer | Incyte Corporation | Completed | Missed primary |
| Phase 2 | NCT04586244 | Jan 2022 → Jan 2024 | urothelial carcinoma | Incyte Corporation | Terminated | Missed primary Stop: Business |
| Phase 2 | NCT04463771 | Jan 2021 → May 2026 | endometrial cancer | Incyte Corporation | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Verzistobart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06056895 ↗ |
| Known as | AGEN-2390 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314786 ↗ |
| Known as | INCAGN02390 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04463771 ↗ |
| Action | Inhibit | “INCAGN02390 (Anti-TIM-3)” NCT04370704 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314786 ↗ |
| Route | Intravenous | “INCAGN02390 administered intravenously” NCT04370704 ↗ |